A Sedation/Cognition/Electroencephalogram (EEG) Study using AZD7325 and Comparator.

Study identifier:D1140C00003

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A phase 1, single centre, single dose, double-blind, double-dummy, four-way crossover, placebo-controlled, randomized study to investigate the effects of AZD7325 on sedation, cognition and electroencephalogram (EEG) in comparison with lorazepam in healthy male volunteers.

Medical condition

Healthy Volunteer

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD7325, AZD7325, AZD7325, AZD7325, AZD7325, AZD7325, AZD7325, AZD7325, AZD7325, AZD7325, AZD7325, AZD7325, Lorazepam, Lorazepam, Lorazepam, Lorazepam, Lorazepam, Lorazepam, Lorazepam, Lorazepam

Sex

Male

Actual enrollment

16

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 01 Jun 2008
Primary Completion Date: 01 Aug 2008
Study Completion Date: 01 Aug 2008

Study design

Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria